Schneider Eugene, EVP and Chief Clinical Development Officer at Ionis Pharmaceuticals (IONS), has demonstrated a clear selling bias in recent years, with no open-market purchases recorded since at least 2024. SEC Form 4 filings reveal 28 transactions totaling $4.3 million in sales against $1.3 million in acquisitions (likely option exercises), all concentrated in IONS. The most recent disposals occurred in rapid succession: a $412,486 sale on March 19, 2026, followed by a $515,630 transaction on January 30, 2026, and a $703,138 sale on January 16, 2026. These follow a pattern of mid-to-high six-figure disposals, including two September 2025 sales totaling $1.2 million and a $408,701 transaction in August 2025.
The transaction history shows Schneider consistently reducing holdings through both routine and larger block sales. While some filings with $0 values indicate option awards or holdings adjustments, the monetization trend is unambiguous. The largest single sale occurred on September 3, 2025 ($753,039), with only one transaction below $50,000 (a $47,780 sale in January 2025). The absence of recent buys and clustering of sales in early 2026 suggests an ongoing effort to liquidate positions systematically. All activity remains confined to Ionis Pharmaceuticals, where Schneider holds a senior clinical development role.
AI-assisted summary